In our first episode, we brought you a discussion of biosimilar interchangeability from experts across the biosimilars landscape. Interchangeable biosimilars haven’t yet become a reality in the US marketplace, and, as of yet, there is no pharmacy-level substitution of interchangeable biosimilars for brand-name products.

However, patients and their providers may still face a change of biologic therapies when payers institute a nonmedical switch.

In today’s episode of Not So Different, you’ll hear providers and patient advocates on the issue of nonmedical switching among brand-name biologics and biosimilars in rheumatology and oncology indications.

Podcasts

In this episode of Not So Different, you’ll hear providers and patient advocates on the issue of nonmedical switching among brand-name biologics and biosimilars in rheumatology and oncology indications.

Episode 2 of "Not So Different: a Podcast From the Center for Biosimilars"  

The introduction of biosimilars into the US marketplace has been cause for both excitement and concern, as these products hold the potential to drive down costs and increase patient access, but face significant challenges to uptake. One of those challenges is interchangeability.

Federal law provides for interchangeable biosimilars, but the FDA has not yet granted that status to any biosimilar product, and hasn’t finalized its guidance on demonstrating interchangeability with a reference product. In this episode of "Not So Different," you’ll hear expert viewpoints on the issue of interchangeability from stakeholders across the biosimilars landscape.

In this innaugural episode of "Not So Different," you’ll hear expert viewpoints on the issue of interchangeability from stakeholders across the biosimilars landscape.

 

Podcasts

Episode 2 of "Not So Different: a Podcast From the Center for Biosimilars"

Introducing "Not So Different: a Podcast From The Center for Biosimilars"